Sixth Annual Multidisciplinary Symposium on Head and Neck Cancer

Venue: Hyatt Regency Philadelphia at Penn’s Landing

Location: Philadelphia, Pennsylvania, United States

Event Date/Time: Oct 16, 2010 End Date/Time: Oct 16, 2010
Report as Spam

Description

Overview and Purpose
The Sixth Annual Multidisciplinary Symposium on Head and Neck Cancer addresses advances in our understanding of the biology and treatment of head and neck cancer. Timely topics such as biomarkers, including HPV and other emerging prognostic/predictive markers, and the multimodality management of locally advanced disease, including surgical approaches, radiation therapy, and chemoradiation therapy, will be addressed. Current data on targeted agents such as inhibitors of EGFR and other novel agents will be presented. Finally, chemoprevention in head and neck cancer will be discussed. In addition to didactic lectures, case-based panel discussions, question-and-answer sessions, the symposium will feature a lunchtime multidisciplinary case management session illustrating the interaction and cooperation between the different branches of oncology.

Lecture topics include:

What Do We Know About HPV in 2010?
Emerging Prognostic/Predictive Biomarkers: Beyond HPV
New Surgical Approaches to Head and Neck Cancer
New Radiation Techniques in Head and Neck Cancer
Reirradiation With Curative Options in Patients With Recurrent Disease
Optimizing the Use of EGFR Inhibitors
Novel Therapeutics in Head and Neck Cancer
Chemoradiation Therapy Strategies for Nonsurgical Patients
Chemoprevention in Head and Neck Cancer
Full agenda and faculty list available soon

Target Audience
This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with head and neck cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of head and neck cancer are also invited to attend.

Learning Objectives
At the conclusion of this symposium, you should be able to:

Evaluate the use of chemoprevention to inhibit the development of head and neck cancer
Discuss differential treatment outcomes to therapy in patients with head and neck cancer based on HPV status
Assess the role of emerging molecular markers to predict response to therapy in head and neck cancer
Discuss new surgical strategies in patients with head and neck cancer
Evaluate new approaches to optimize radiation therapy in head and neck cancer
Assess the efficacy and safety of chemoradiation in nonsurgical patients with head and neck cancer
Evaluate clinical data on EGFR inhibitors in metastatic head and neck cancer
Discuss the efficacy and safety of novel targeted agents in head and neck cancer
Assess potential benefits of clinical trials for individual patients with head and neck cancer

Venue